HAYWARD, Calif.--(BUSINESS WIRE)--Dec. 15, 2017--
Pulse Biosciences, Inc. (NASDAQ: PLSE), a medical technology company
developing a proprietary therapeutic tissue treatment based on its
Nano-Pulse Stimulation (NPS) platform, today announced that the
Compensation Committee of the company’s Board of Directors granted
non-qualified stock options to purchase an aggregate of 121,000 shares
of Pulse Biosciences common stock to seven (7) new employees under Pulse
Biosciences, Inc. 2017 Inducement Equity Incentive Award Plan.
The 2017 plan is used exclusively to grant equity awards to individuals
who were not previously an employee or non-employee director of Pulse
Biosciences as an inducement material to such individual's entering into
employment with Pulse Biosciences in accordance with Nasdaq Marketplace
Rule 5635(c)(4).
The options have an exercise price of $24.78 per share, which is equal
to the closing price of Pulse Biosciences common stock on December 15,
2017. Each option will vest and become exercisable as to 25% of the
shares on the first anniversary of the recipient’s start date, and will
vest and become exercisable as to the remaining 75% of the shares in 36
equal monthly installments following the first anniversary, subject to
each employee’s continued employment with Pulse Biosciences on these
vesting dates. The options are subject to the terms and conditions of
Pulse Bioscience’s 2017 Employment Inducement Equity Incentive Award
Plan, and the award agreements entered into with each recipient.
About Pulse Biosciences
Pulse Biosciences is a medical technology company developing a
therapeutic tissue treatment platform based on Nano-Pulse Stimulation
(NPS), a proprietary high-speed cell signaling technology. NPS is a
non-thermal, precise, focal drug-free tissue treatment technology that
directly affects the cell membrane and intracellular structures to
stimulate unique behaviors in cells. NPS can initiate a cell death
process. That process provides a means for the treatment of tissue cells
with minimal inflammatory response. This has the potential to improve
healing outcomes. This process may also contribute to the replacement of
treated tissue cells with healthy new tissue cells. In cancerous
lesions, NPS has been shown in preclinical models to induce immunogenic
cell death (ICD) exposing the unique antigens of the treated cells to
the immune system, resulting in the generation of cytotoxic T-cells and
the mounting of an adaptive immune response targeted against those
cells. Pulse Biosciences is investigating a variety of applications for
its technology that exploits the technology’s unique biologic effect.
More information is available at www.pulsebiosciences.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171215005884/en/
Source: Pulse Biosciences, Inc.
Pulse Biosciences, Inc.
Investors:
Brian Dow
Sr.
Vice President and Chief Financial Officer
IR@pulsebiosciences.com
or
The
Trout Group
Mike Zanoni, 646-378-2924
mzanoni@troutgroup.com
or
Media:
Sam
Brown, Inc.
Christy Curran, 615-414-8668
christycurran@sambrown.com
